The company launched ONAPGO™, a new treatment for Parkinson's disease, in April 2025 and saw significant growth in Qelbree prescriptions, which rose by 22%. Supernus reiterated its full year ...

Supernus Pharmaceuticals Inc (SUPN) reports robust Qelbree sales and strategic advancements, despite facing increased losses ...

Early in the second quarter, we launched ONAPGO, Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults ...

Discussion on ONAPGO's launch highlighted initial positive reception and the expectation of moderate sales contributions in 2025. Analysts expressed cautious optimism, focusing on growth ...

Supernus Pharmaceuticals, Inc. First quarter 2025 net sales of Qelbree ® increased 44% to $64.7 million, compared to the same period in 2024. First quarter 2025 net sales of GOCO ...

First quarter 2025 net sales of Qelbree ® increased 44% to $64.7 million, compared to the same period in 2024. First quarter 2025 net sales of GOCOVRI ® increased 16% to $30.7 million, compared to the ...

"In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson's disease who are experiencing motor ...

Q1 2025 Management View CEO Jack Khattar highlighted double-digit revenue growth from core products, excluding legacy products Trokendi XR and Oxtellar XR. These core products achieved a 26% increase ...

First quarter adjusted operating earnings (non-GAAP) (1) increased 16% to $25.9 million. ONAPGO™ (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year ...

“In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson’s disease who are ...